GSK Reconfirms Full-Year Guidance Amid Specialty Medicine Growth and Pipeline Expansion
GSK (GSK) has reconfirmed its full-year 2026 guidance following a third-quarter performance characterized by a 5% increase in sales to GBP 8.9 billion. The company is successfully transitioning its portfolio from legacy primary-care treatments toward high-margin specialty therapies, which saw a 15% growth rate during the third quarter. This shift is bolstered by strong commercial momentum in long-acting HIV treatments like Cabenuva. To support long-term organic growth, GSK is aggressively accelerating its R&D pipeline, having initiated 18 phase 3 clinical trials in 2026 with plans to reach 22 by year-end. Additionally, the company's 'Accelerate Growth' restructuring program is streamlining operations and supply chain logistics to redirect savings into late-stage drug development while maintaining stable operating profit margins.

Tickers: $GSK
Topics: clinical trials pharmaceuticals revenue growth specialty medicines
Read the full article at Motley Fool
Part of the story Materialise Reconfirms Full-Year Revenue Guidance Amid Growth in Medical and Series Manufacturing (2 articles)